Format

Send to

Choose Destination
Nat Rev Cancer. 2012 Mar 1;12(4):307-13. doi: 10.1038/nrc3246.

The determinants of tumour immunogenicity.

Author information

1
Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Strasse 10, Berlin 13125, Germany. tblanke@mdc-berlin.de

Abstract

Many standard and targeted therapies, as well as radiotherapy, have been shown to induce an anti-tumour immune response, and immunotherapies rely on modulating the host immune system to induce an anti-tumour immune response. However, the immune response to such therapies is often reliant on the immunogenicity of a tumour. Tumour immunogenicity varies greatly between cancers of the same type in different individuals and between different types of cancer. So, what do we know about tumour immunogenicity and how might we therapeutically improve tumour immunogenicity? We asked four leading cancer immunologists around the world for their opinions on this important issue.

PMID:
22378190
PMCID:
PMC3552609
DOI:
10.1038/nrc3246
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center